How KRAS G12C Inhibitors Work in Cancer Treatment: A Molecular Guide

KRAS G12C inhibitors bind the mutant KRAS protein and keep it in an inactive, GDP-bound state. This reduces signaling through pathways that help cancer cells grow. The G12C mutation adds a cysteine to KRAS, giving certain inhibitors a site where they can form a covalent bond.

This mechanism explains the drugs’ selectivity and one of their limits: they can block KRAS G12C, but other changes may restore growth signaling in tumors. Sotorasib and adagrasib are examples of drugs in this class. Their use depends on the cancer type, the patient’s treatment history, and the relevant drug approval.

Why the G12C mutation can be targeted

KRAS is a small GTPase, a protein that switches between an active state bound to GTP and an inactive state bound to GDP. In its active state, KRAS can send signals through pathways such as RAF–MEK–ERK, which regulate cell growth and survival.

The G12C mutation replaces glycine with cysteine at position 12. The cysteine has a reactive, sulfur-containing group that inhibitors can bind. Drugs such as sotorasib and adagrasib fit into a pocket near the switch II region of KRAS and form a covalent bond with the mutant cysteine. This binding site is separate from the pocket that holds GTP or GDP.

Wild-type KRAS and other KRAS variants, such as G12D and G12V, do not have cysteine at position 12. This difference helps G12C inhibitors target the mutant protein selectively. It does not mean that all possible off-target effects are absent. Selectivity describes a drug’s preference for its intended target.

How covalent binding reduces signaling

Sotorasib and adagrasib bind preferentially to KRAS G12C in its inactive, GDP-bound state. Once attached, an inhibitor prevents that KRAS molecule from switching back to its active, GTP-bound state. The drug does not compete with GTP for the nucleotide-binding site. Instead, it binds elsewhere on the protein and captures KRAS in its inactive state.

With fewer active KRAS G12C molecules, signaling to downstream proteins such as RAF, MEK, and ERK can decrease. This may slow tumor growth or cause a tumor to shrink. Responses vary: a tumor may respond strongly, respond partly, or show little response, depending on its biology and other factors.

The covalent bond is effectively irreversible for the KRAS molecule it binds. Inhibition of that molecule lasts until the cell breaks it down. The cell can also make new KRAS protein, so the drug does not permanently disable all KRAS G12C in the tumor. This helps explain why treatment follows a continuing schedule set by the drug label and the treating clinician.

These drugs interfere with one signaling protein. They do not remove the mutation from the cancer or guarantee that every cancer cell depends on KRAS G12C to the same degree.

Clinical use and resistance

Sotorasib received FDA accelerated approval for adults with KRAS G12C-mutated non-small cell lung cancer (NSCLC) in a specified treatment setting FDA. Other drugs in this class, including adagrasib, also target KRAS G12C. Their clinical use and regulatory status can differ, so treatment decisions should follow current guidance and take the individual patient’s situation into account.

A response to a KRAS G12C inhibitor may not last. Cancer cells can acquire or select changes that reduce the drug’s effect or restore growth signals. Resistance mechanisms differ among tumors and may include:

• Changes in KRAS: Additional alterations can affect drug binding or favor the active state of KRAS.
• Increased upstream signaling: Proteins such as receptor tyrosine kinases can stimulate pathways that feed into RAS signaling.
• Alternative routes downstream: Changes in signaling proteins farther along the pathway can help cancer cells maintain growth signals despite KRAS inhibition.

Researchers are studying combinations of KRAS G12C inhibitors with other targeted drugs, including inhibitors of proteins involved in upstream or downstream signaling. Combining treatments can also increase side effects, so the risks and benefits need assessment in clinical trials and care settings. A combination that works for one tumor type or patient group may not suit another.

One example: from test result to treatment target

Suppose genetic testing of an NSCLC tumor identifies a KRAS G12C mutation. The result tells the care team that the tumor has the specific cysteine alteration targeted by drugs such as sotorasib. The result alone does not determine which treatment is appropriate. The team also considers the cancer’s stage, previous treatments, other test results, the patient’s health, and current treatment guidance.

If the team chooses a KRAS G12C inhibitor, the drug can bind the mutant protein when it is GDP-bound and prevent it from returning to its active state. Reduced KRAS signaling may slow the cancer or shrink the tumor. If the cancer later progresses, the cause could be a resistance change or another factor. Further testing may help guide decisions, but the usefulness of a repeat biopsy or blood-based test depends on the clinical situation.

The mutation matters because it identifies a specific drug target. It does not predict exactly how much a tumor will respond or how long a response will last.

Key Takeaways

• KRAS G12C inhibitors bind the cysteine created by the G12C mutation and hold the protein in its inactive, GDP-bound state.
• By reducing active KRAS signaling, these drugs can lower signaling through pathways such as RAF–MEK–ERK.
• Sotorasib and adagrasib are examples of KRAS G12C inhibitors. Their use depends on the cancer type, treatment history, and applicable guidance.
• Tumors can develop resistance through changes in KRAS or through other signaling routes. Combination approaches are under study.
• A KRAS G12C test identifies a potential target, but an oncologist must consider the full clinical picture when choosing treatment. National Cancer Institute